Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial

被引：0

作者：

Broeckelmann, Paul J. ^{[1
]}

Buehnen, Ina ^{[1
]}

Herhaus, Peter ^{[2
]}

Meissner, Julia ^{[3
]}

Trautmann-Grill, Karolin ^{[4
]}

Mueller, Horst ^{[1
]}

Fuchs, Michael ^{[5
,6
]}

von Tresckow, Bastian ^{[7
]}

Borchmann, Peter ^{[8
]}

Engert, Andreas ^{[1
]}

Behringer, Karolin ^{[1
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, German Hodgkin Study Grp GHSG, Cologne, Germany

[2] Tech Univ Munich, Clin & Policlin Internal Med 3, Sch Med, Klinikum Rechts Isar, Munich, Germany

[3] Univ Hosp Heidelberg, Med 5, Heidelberg, Germany

[4] Univ Hosp Carl Gustav Carus, Med Clin 1, Dresden, Germany

[5] Univ Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Dept Internal Med 1, Med Fac, Cologne, Germany

[6] Univ Hosp Cologne, Cologne, Germany

[7] West German Canc Ctr Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany

[8] Univ Hosp Cologne, Dept Internal Med 1, German Hodgkin Study Grp GHSG, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188734

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Changes in patient-reported outcomes during the SENSE Trial: first-line treatment with 2 NRTIs plus etravirine or efavirenz for 48 weeks
Miralles Alvarez, C.
Clotet, B.
Nelson, M.
Uglietti, A.
Hill, A.
van Delft, Y.
Marks, S.
ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
[22] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3
Makharadze, Tamta
Quek, Ruben G. W.
Melkadze, Tamar
Gogishvili, Miranda
Ivanescu, Cristina
Giorgadze, Davit
Dvorkin, Mikhail
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa
Gessner, Christian
Moreno-Jaime, Brizio
Passalacqua, Rodolfo
Konidaris, Gerasimos
Rietschel, Petra
Gullo, Giuseppe
CANCER, 2023, 129 (14) : 2256 - 2265
[23] Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial
Broeckelmann, Paul J.
Boell, Boris
Molin, Daniel
Schneider, Gundolf
Leppae, Sirpa
Meissner, Julia
Kamper, Peter
Hutchings, Martin
Christensen, Jacob Haaber
Schnetzke, Ulf
Fuchs, Michael
Eichenauer, Dennis A.
von Tresckow, Bastian
Kaul, Helen
Borchmann, Peter
Fossa, Alexander
BLOOD, 2024, 144 : 3055 - 3055
[24] Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes
Blanco, Remei
Domine, Manuel
Gonzalez, Jose Luis
Loutfi, Sami
Alfaro, Jordi
Saldana, Juana
Rubio, Jaime
Campos, Begona
Hidalgo, Julia
Barba, Andres
Marquez, Diego
Martin, Maria
Olaverri, Amaya
Nadal, Ernest
LUNG CANCER, 2023, 183
[25] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Vogel, Arndt
Qin, Shukui
Kudo, Masatoshi
Su, Yun
Hudgens, Stacie
Yamashita, Tatsuya
Yoon, Jung-Hwan
Fartoux, Laetitia
Simon, Krzysztof
Lopez, Carlos
Sung, Max
Mody, Kalgi
Ohtsuka, Tatsuroh
Tamai, Toshiyuki
Bennett, Lee
Meier, Genevieve
Breder, Valery
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (08): : 649 - 658
[26] APPROACH AND FEASIBILITY OF PATIENT-REPORTED OUTCOMES IN A PHASE III CLINICAL TRIAL FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS
Castellino, S. M.
Henderson, T. O.
Keller, F.
Kelly, K.
Curtis, R.
Conti, R. M.
Parsons, S. K.
HAEMATOLOGICA, 2016, 101 : 37 - 37
[27] Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
Ooki, Akira
Morita, Satoshi
Iwamoto, Shigeyoshi
Hara, Hiroki
Tanioka, Hiroaki
Satake, Hironaga
Kataoka, Masato
Kotaka, Masahito
Kagawa, Yoshinori
Nakamura, Masato
Shingai, Tatsushi
Ishikawa, Masashi
Miyake, Yasuhiro
Suto, Takeshi
Hashiguchi, Yojiro
Yabuno, Taichi
Sakamoto, Junichi
Tsuji, Akihito
Ando, Masahiko
Yamaguchi, Kensei
CANCER MEDICINE, 2020, 9 (05): : 1779 - 1789
[28] Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK plus NSCLC
Mazieres, J.
Iadeluca, L.
Shaw, A.
Solomon, B.
Bauer, T.
De Marinis, F.
Felip, E.
Goto, Y.
Kim, D.
Mok, T.
Reisman, A.
Thurm, H.
Polli, A.
Liu, G.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S175 - S176
[29] Outcomes of First-Line Treatment (FL) of Classical Hodgkin Lymphoma (cHL) in Argentina: A Real Life Multicenter Retrospective Study
Otero, Victoria
Valeria Mahuad, Carolina
Korin, Laura
Martinez, Enriqueta
Warley, Fernando
Garcia Rivello, Hernan
Cristaldo, Nancy
Kohan, Dana
Zerga, Marta
Martin Garate, Gonzalo
Vicente Reparaz, Maria De Los Angeles
Florencia Aizpurua, Maria
Rojas Bilbao, Erica
Cerana, Susana
Eugenia Funes, Maria
Plaza, Iliana
Cecilia Foncuberta, Maria
Vijnovich Baron, Anahi
Cranco, Santiago
Vitriu, Adriana
Gomez, Mariela
Lavalle, Justina
Casali, Claudia
Clavijo, Manuela
Melillo, Luciana
Cabral Lorenzo, Maria Cecilia
Miroli, Augusto
Fishman, Laura
Pavlove, Maximiliano J.
Miodosky, Marcela
Cugliari, Silvana
BLOOD, 2019, 134
[30] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Scherpereel, A.
Antonia, S.
Bautista, Y.
Grossi, F.
Kowalski, D.
Zalcman, G.
Nowak, A.
Fujimoto, N.
Peters, S.
Tsao, A.
Mansfield, A.
Popat, S.
Sun, X.
Padilla, B.
Aanur, P.
Daumont, M.
Bennett, B.
McKenna, M.
Baas, P.
ANNALS OF ONCOLOGY, 2020, 31 : S1441 - S1441

← 1 2 3 4 5 →